Compare RLMD & VALU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RLMD | VALU |
|---|---|---|
| Founded | 2004 | 1931 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 307.3M | 340.4M |
| IPO Year | N/A | N/A |
| Metric | RLMD | VALU |
|---|---|---|
| Price | $4.34 | $37.55 |
| Analyst Decision | Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $5.50 | N/A |
| AVG Volume (30 Days) | ★ 1.1M | 3.1K |
| Earning Date | 11-13-2025 | 12-15-2025 |
| Dividend Yield | N/A | ★ 3.42% |
| EPS Growth | N/A | ★ 6.17 |
| EPS | N/A | ★ 2.26 |
| Revenue | N/A | ★ $34,801,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $16.85 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.24 | $32.94 |
| 52 Week High | $5.12 | $55.01 |
| Indicator | RLMD | VALU |
|---|---|---|
| Relative Strength Index (RSI) | 61.38 | 54.29 |
| Support Level | $3.95 | $37.07 |
| Resistance Level | $4.72 | $39.20 |
| Average True Range (ATR) | 0.46 | 0.81 |
| MACD | -0.07 | 0.23 |
| Stochastic Oscillator | 62.79 | 65.88 |
Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its key product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications.
Value Line Inc is a U.S based company. It produces investment periodicals based on underlying research and making available copyright data, including ranking system and other information, to third parties under written agreements for use in third-party managed and marketed investment products and for other purposes. The company markets under brands including Value Line, the Value Line logo, The Value Line Investment Survey, Smart Research, Smarter Investing and a trusted name in Investment Research. Its only operating segment being Publishing.